BIOMARKER DATA
Biomarker
Cancer Type
Literature Cited
VEGF
Breast, Lung
PDGFRβ
Breast
Vlahovic, G., Z.N. Rabbani, et al. (2006). “Treatment with imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-β and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation.” Br J Cancer. 95(8): 1013-1019.
Paulsson, J., T. Sjoblom, et al. (2009). “Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.” Am J Pathol. 175(1): 334-41.
Yang, S. X., S. M. Steinberg, et al. (2008). “Gene expression profile and angiogenic marker correlates of response to neoadjuvant bevacizumab (BV) followed by BV plus chemotherapy in breast cancer.” Clin Cancer Res. 14(18): 5893-5899.
CD31
Breast, Ovarian
Goodheart M.J., J.M.Ritchie, et al. (2005). “The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 11(10): 3733-42.
Yang, S. X., S. M. Steinberg, et al. (2008). “Gene expression profile and angiogenic marker correlates of response to neoadjuvant bevacizumab (BV) followed by BV plus chemotherapy in breast cancer.” Clin Cancer Res. 14(18): 5893-5899.
ALK
Lung
Shaw, A., B. Yeap, et al. (2009). “Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK.” Journal of Clinical Oncology. 27(26): 4247-4253.
Bang, Y., E.L. Kwak, et al. (2010). “Clinical activity of the oral ALK inhibitor PF-02341066 in ALK-positive patients with non-small cell lung cancer (NSCLC).” Journal of Clinical Oncology. 28:18S – abstract 3.
EGFR
Lung
KRAS
Colon, Lung
PI3K
Breast, Colon
HER2
Ovarian
PTEN
Colon, Endometrial
Loupakis, F., L. Pollina, et al. (2009). “PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.” Journal of Clinical Oncology. 27(16): 2622-2629.Frattini, M., P. Saletti, et al. (2007). “PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients.” British Journal of Cancer. 97: 1139-1145.
Perrone, F., A. Lampis, et al. (2009). “PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients.” Annals of Oncology. 20: 84-90. Nagata, Y., K.H. Lan, et al. (2004). “PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.” Cancer Cell. 6: 117-127.
ERCC1
Lung, Ovarian
BRCA1
Ovarian
MSI Panel: MLH1/MSH2/MSH6/PMS2
Colon
Topo2α
Lung, Ovarian
Ki-67
Breast, Colon, Lung